Context Partners Fund’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Context Partners Fund’s Portfolio NVLN Stock Details NVLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	$189K	Buy	+63,734	New	+$226K	0.11%	67

Other funds holding NVLN

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Context Partners Fund's NVLN Position: Q3 2018 in Review

Context Partners Fund opened a new position in Novelion Therapeutics Inc. Common Shares (NVLN) in Q3 2018: 63,734 shares worth $189K. The stake represents 0.11% of the portfolio and ranks #67 among its holdings.

49 funds tracked by Wall St. Rank hold NVLN as of Q3 2018.

Context Partners Fund held 63,734 shares of Novelion Therapeutics Inc. Common Shares worth $189K as of Q3 2018.
Novelion Therapeutics Inc. Common Shares was a new Context Partners Fund position in Q3 2018.
Novelion Therapeutics Inc. Common Shares made up 0.11% of Context Partners Fund's portfolio in Q3 2018, its #67 holding.
49 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q3 2018.

Based on Context Partners Fund's 13F filing for Q3 2018, filed 1 Nov 2018.